Home ›
Leukemia Trials ›
NCT07036250
Clinical Study of U32 in Patients With Acute Myeloid Leukemia
This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.
Trial Details
NCT ID NCT07036250
Phase PHASE1 / PHASE2
Sponsor Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Suzhou, China|31.30408,120.59538
Key Eligibility Criteria
Voluntarily sign the informed consent form and be expected to complete the follow-up examinations and treatments as required by the study protocol. Be aged ≥2 years and ≤65 years at the time of signing the informed consent form, with no restrictions on gender. Meet the AML diagnosis according to the 2022 WHO classification and satisfy the diagnostic criteria for relapsed and refractory acute myeloid leuke… AML patients who are molecularly positive after treatment and cannot achieve negativity through conventional therapy.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →